Search clinical trials for: AZD8848

Total 35 results

AstraZeneca

Completed

A Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 on the Response on Biomarkers

Healthy Volunteers

Sweden
AstraZeneca

Completed

Study to Investigate the Safety and Tolerability of AZD8848 in Butyrylcholinesterase Deficient Subjects

Butyrylcholinesterase Deficiency

Denmark
AstraZeneca

Completed

AZD8848 Single Ascending Dose Study

Healthy

United Kingdom
AstraZeneca

Completed

The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen

Allergic Asthma

United Kingdom
AstraZeneca

Completed

Tolerability/Safety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season (SAD)

Healthy | Allergic Rhinitis

Sweden
AstraZeneca

Completed

Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848

Allergic Rhinitis

Sweden
AstraZeneca

Completed

Safety, Tolerability and Pharmacokinetics of Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers

Healthy

Japan
AstraZeneca

Completed

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD5847 After Multiple Doses Over 14 Days

Healthy

United States
AstraZeneca
Parexel

Terminated

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of AZD9898

Asthma

United Kingdom
AstraZeneca

Completed

Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (TOP)

Chronic Obstructive Pulmonary Disease (COPD)

Sweden, Denmark, Finland, Netherlands, Norway
AstraZeneca

Terminated

This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses

Healthy

United States
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects

Healthy Subjects | Safety, | Tolerability,

United Kingdom
AstraZeneca
Parexel

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects

Chronic Obstructive Pulmonary Disease

United Kingdom
AstraZeneca
Parexel; Covance; The Doctors Laboratory; Industrias Farmacéuticas Almirall S.A.

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects

Chronic Obstructive Pulmonary Disease - COPD

United Kingdom
AstraZeneca

Completed

Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects

Asthma (Part 1) | COPD (Part 2)

United Kingdom
AstraZeneca
Parexel

Completed

Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871

Chronic Obstructive Pulmonary Disease COPD

Germany, United Kingdom
AstraZeneca

Completed

Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848

Allergic Rhinitis

Sweden
AstraZeneca

Completed

AZD8108 SAD/MAD in Healthy Volunteers (AZD8108)

Healthy Volunteers

United States
AstraZeneca
Quintiles, Inc.

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers

Healthy

United States
AstraZeneca

Recruiting

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
Alcon Research

Completed

First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration

Age-Related Macular Degeneration
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

COVID-19

United States, Belgium, France, Spain, United Kingdom
AstraZeneca

Completed

Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

Corona Virus Disease

United States
AstraZeneca

Completed

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

Advanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation

United States, United Kingdom
AstraZeneca
Parexel

Completed

A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

Chronic Obstructive Pulmonary Disease

Germany, United Kingdom
AstraZeneca
ImaginAb, Inc.

Terminated

A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

Carcinoma, Non-Small-Cell Lung | Urinary Bladder Neoplasms | Colorectal Cancer

United States, Canada
AstraZeneca

Terminated

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 (ENDURE)

Coronavirus Disease 2019 (COVID-19)

United States
The Netherlands Cancer Institute
Leiden University Medical Center; University Medical Center Nijmegen

Recruiting

Sarcomas and DDR-Inhibition; a Combined Modality Study (SADDRIN-1)

Soft Tissue Sarcoma Adult

Netherlands
AstraZeneca
Parexel

Completed

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

Advanced Malignancies

United Kingdom, United States
National Institute of Allergy and Infectious Diseases...
National Heart, Lung, and Blood Institute (NHLBI); AstraZeneca; University of... and other collaborators

Active, not recruiting

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

COVID-19

United States, Denmark, Greece, Poland, Singapore, Spain, Switzerland, Uganda, United Kingdom
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults (STORM CHASER)

COVID-19

United States, United Kingdom
AstraZeneca

Completed

Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults (TACKLE)

COVID-19

United States, Spain, United Kingdom, Brazil, Germany, Ukraine, Japan, Italy, Poland, Russian Federation, Mexico, Czechia, Argentina, Hungary, Peru
National Institute of Allergy and Infectious Diseases...
Eli Lilly and Company; National Heart, Lung, and Blood Institute (NHLBI); Gla... and other collaborators

Completed

ACTIV-3: Therapeutics for Inpatients With COVID-19 (TICO)

Covid19

United States, Denmark, Greece, Nigeria, Poland, Singapore, Spain, Switzerland, Uganda, United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Phase 2a EBA Trial of AZD5847

Tuberculosis

South Africa
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AIDS Clinical Trials... and other collaborators

Completed

ACTIV-2: A Study for Outpatients With COVID-19

Covid19 | Coronavirus

United States, Argentina, Brazil, Guatemala, Mexico, Philippines, Puerto Rico, South Africa, Canada

Search clinical trials for: AZD8848

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations